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Objective: This study aimed to prospectively investigate the incidence of first
thromboembolic events (TEs) in a cohort of systemic lupus erythematosus (SLE)
patients. The patients were positive for anti-phosphatidylserine/prothrombin (aPS/PT)
antibodies and tested negative for anticardiolipin (aCL) and anti-β2–glycoprotein I
(aβ2GPI) antibodies [regardless of their Lupus Anticoagulant (LA) status].
Methods: Inclusion criteria included: (a) SLE with no previous TEs; (b) no concomitant
anti-thrombotic therapy; (c) isolated confirmed positive test for aPS/PT.
Results: From the total of 52 SLE patients (42, 80.8%women), 18 patients (34.6%) were
found to be positive for aPS/PT (IgG/IgM). During a mean follow-up (3.9 ± 1.1 years),
3 TEs occurred (1.3%/year). The overall cumulative incidence of TEs was 5.8% after 2
years, and up to 16.7% when focusing on aPS/PT positive patients. All the TEs events
(two cerebrovascular events and one thrombotic kidney microangiopathy) occurred in
the aPS/PT positive group. When focusing on IgG aPS/PT, we found that patients who
tested positive were at a significantly higher risk for TEs (crude HR 19.6, 95%; CI 1.1 to
357.6; p < 0.05) compared to patients with negative aPS/PT.
Conclusion: This study observed a rate of TEs of 1.3%/year, in aPS/PT positive only
patients. Our prospective data suggest that aPS/PT might confer an increased risk for
the development of TEs in SLE patients.
Keywords: antiphospholipid syndrome, antiphospholipid antibodies, anti-phosphatidylserine/prothrombin,
aPS/PT, non-criteria aPL, thrombosis, systemic lupus erythematosus
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INTRODUCTION
Multiple positivity in tests investigating the presence of
antiphospholipid antibodies (aPL) [criteria aPL comprehend:
lupus anti-coagulant (LA), anticardiolipin (aCL), and anti-
β2–glycoprotein I (aβ2GPI) antibodies] are now widely
recognized as being associated with a higher risk of developing
thromboembolic events (TEs). The concomitant presence of
all criteria aPL (triple positive patients) is associated with
thrombosis and identifies high-risk patients in antiphospholipid
syndrome (APS) setting (1). However, some individuals
may show a clinical picture that strongly indicates APS
even though they are persistently negative for criteria
aPL tests. Current research examines testing for other aPL
specificities to fill this diagnostic and therapeutic gap. When
investigating these so-called “extra-criteria” aPL in a patient
with clinical manifestations suggestive of APS, testing for
anti-phosphatidylserine/prothrombin (aPS/PT) antibodies has
been recommended as a further tool in guiding the management
of these patients. It can be particularly relevant when there is an
absence of criteria aPL or as a part of risk assessment approaches
(2). This approach to testing has been analyzed by two systematic
reviews (3, 4), which outline that aPS/PT antibodies might be
considered a strong risk factor for TEs independently from sites
and type of thrombosis. There is little data, available to provide
prospective validation of the role the absence of other aPL tested
by β2GPI-dependent assays.
This study prospectively investigates the incidence of first
TE in a cohort of systemic lupus erythematosus (SLE) patients
positive for aPS/PT antibodies who also tested negative for




Since 2015, aPS/PT has formed part of routine testing in SLE
patients as part of the autoantibody screening of consecutive
patients attending the S. Giovanni Bosco Hospital (Turin, Italy).
The patients included in this study were diagnosed with SLE
according to the 1982 revised criteria (5), received prospective
follow-up, and fulfilled the following criteria:
1) no previous TEs events;
2) no concomitant anti-coagulant nor anti-platelets therapy;
3) tested negative for criteria aPL solid assay aCL and aβ2GPI
(confirmed at least twice, at least 12 weeks apart), regardless of
their LA status.
All included patients were tested for aPS/PT, and both IgG and
IgM, at study inclusion.
Positive aPS/PT testing was defined as having at least two
positive test results (IgG and/or IgM), at least 12 weeks apart. The
disposition of patients is illustrated in Figure 1.
All subjects provided written consent according to the
Declaration of Helsinki. This study was performed according to
the local legislation of Rare Diseases in Piedmont (Northwest
Italy) (protocol. n. 1577/UC/SAN 11.10.2005).
Data Collection
Data on demographic, and laboratory and clinical features were
prospectively collected every 6 months or at the time of any new
clinical event for each patient. Patients with a previous history
of TEs were excluded based on patient interviews and available
hospital records.
Assessed arterial thrombotic risk factors were diabetes
mellitus, arterial hypertension, hypercholesterolemia, obesity,
smoking habit, and positive family medical history. Assessed
venous risk factors were the following: ongoing hormonal
replacement therapy, active pregnancy, malignancy, positive
family medical history, and thrombophilia (including
antithrombin, protein C, or protein S; factor V Leiden;
prothrombin G20210A mutation; hyperhomocysteinemia, high
factor VIII levels).
Outcome Events
TEs had to be objectively diagnosed during the follow-up. TEs
reports include type, site, SLE activity assessed by the Systemic
Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
and ongoing medications at the time of event.
Venous thromboembolism (VTE) was assessed by
compression ultrasonography or venography in case of
deep vein thrombosis, and spiral tomography, ventilation-
perfusion lung scan, or pulmonary angiography in case of
pulmonary embolism. Intracerebral thrombosis was assessed
by computed tomographic scanning, magnetic resonance
imaging, or angiography; retinal thrombosis was evaluated by
ophthalmologic examination. Peripheral- or mesenteric- artery
thrombosis was documented by arteriography or at the surgery
table. Small-vessel thrombosis was evaluated by appropriate
imaging study or histopathology in the absence of inflammation
in the vessel wall. Acute myocardial infarction was defined
in the presence of a typical clinical presentation associated
with typical electrocardiographic features and elevated cardiac
enzymes (CK-MB or troponins I or T). Stoke/transient ischemic
attack was defined according to standard definitions (transient
ischemic attack was considered for analysis only if cerebral
imaging confirmed cerebral ischemia).
aPL Testing
Complete aPL profile at inclusion in the present study included:
LA, aCL IgG/IgM, aβ2GPI IgG/IgM, aPS/PT IgG/IgM, and
aβ2GPI Domain 1 (aβ2GPI-D1) IgG.
LA testing was performed according to international
guidelines (6). Solid-phase aPL testing was executed with
chemiluminescent immunoassay (INOVA Diagnostic) for aCL,
aβ2GPI, and aβ2GPI-D1, while aPS/PT testing was performed
using ELISA assay (INOVA Diagnostic). The cut-off values were
determined by manufacturer recommendations. Cut-off values
provided by the manufacturer were independently validated in
a cohort of 100 healthy blood donors, and the used values were
above the 99th percentile of the distribution. The Global APS
Score (GAPSS) was calculated according to Sciascia et al. (7).
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FIGURE 1 | Patients disposition. Description of the patients selected for the study, according to the inclusion criteria. Patients included in the study were then
separated according to their anti-phosphatidylserine/prothrombin status (positive/negative), and the number of thrombotic events was recorded retrospectively.
aPS/PT, anti-phosphatidylserine/prothrombin; SLE, systemic lupus erythematosus; TE, thrombotic event; aPL, antiphospholipid antibodies; aCL, anticardiolipin;
aβ2GPI, anti-β2–glycoprotein I; LA, lupus anti-coagulant.
Statistics
Descriptive statistics are reported as appropriate: categorical
data are expressed as frequencies (percentage); continuous
data are reported as mean ± SD. The Kaplan-Meier
survival analysis was used to determine the cumulative
incidence of TEs at follow-up. Student’s t-test was
used for normally distributed parameters and the
non-parametric Mann–Whitney test for non-normally
distributed parameters.
The Cox proportional hazards model was initially included in
the statistical plan to detect possible predictors of TEs among the
demographic factors. The initial model computed the following
variables: age> 50 yrs, sex, active SLE assessed by SLEDAI-
2K >6, and any additional thrombotic risk factor (smoking,
arterial hypertension, hyperlipidemia, diabetes, immobilization).
However, taking into account the rate of observed thrombosis,
as the number of primary events per variable can affect the
estimation of the subdistribution hazard competing risks model,
we decided to keep this analysis as exploratory. A Log-rank
test was performed, comparing thrombotic events during the
follow-up according to the aPS/PT positivity.
Statistical significance was considered for p < 0.05. All
analyses were performed using SPSS version 26.0 (IBM, Armonk,
NY, USA).
RESULTS
The demographic and clinical characteristics of the included
patients are described in Table 1.
This study included a total of 52 patients with SLE [42 (80.8%)
females]. Of those, 18 patients (34.6%) were found to be positive
for aPS/PT (IgG and/or IgM).
During a mean follow-up of more than 3.5 years (3.9 ±
1.1 years), three patients developed TEs (1.3% per year). The
overall cumulative incidence of TEs was 5.8% after 2 years, rising
to 16.7% when focusing only on aPS/PT positive SLE patients.
Details on the three patients who developed a TE are shown
in Table 2. All the TEs events (two cerebrovascular events and
one thrombotic kidneymicroangiopathy) occurred in the aPS/PT
positive group. Two patients, one aPS/PT positive and one
aPS/PT negative, experienced superficial thrombophlebitis, not
included among endpoints. No patient died and no pregnancy
was recorded during the follow-up. To confirm the absence of
solid aβ2GPI dependent aPL positive test, all patients were tested
for aβ2GPI-D1, and they all had negative results.
No statistically significant difference was observed between
patients with TEs compared to those without when dividing
for demographic variables (age, sex), SLE features (active SLE
assessed by SLEDAI-2K > 6), and arterial and venous risk factors
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TABLE 1 | Clinical and demographic characteristics.
SLE aPS/PT positive SLE aPS/PT negative
(N = 18) % (N = 34) %
Age
Years (mean ± SD) 47.5 ± 11.5 44.8 ± 13.5
Female
(N; %) 14 77.8 28 82.4
aPS/PT IgG
Positive (N; %) 11 61.1
Titer (mean ± SD; median [range]) 99.8 ± 77.8; 121 [12–229]
aPS/PT IgM
Positive (N; %) 16 88.9
Titer (mean ± SD; median [range]) 126.2 ± 150.8; 131 [8–518]
Lupus anti-coagulant
Positive (N; %) 5 27.8 12 35.3
SLE manifestation
Skin (N; %) 6 33.3 8 23.5
Joints (N; %) 17 94.4 28 82.4
Hematological (N; %) 3 16.7 6 17.6
Lupus Nephritis* (N; %) 8 44.4 11 32.4
Sierositis (N; %) 4 22.2 7 20.6
Follow-up**
Years (mean ± SD; median [range]) 3.7 ± 1.2 3.9 ± 1.1
SLE disease duration
Years (mean ± SD; median [range]) 15.7 ± 8.1 19.7 ± 7.2
Therapy**
Hydroxychloroquine (N; %) 17 94.4 33 97.1
Prednisone < 7.5 mg/die*** (N; %) 14 77.8 22 64.7
Cyclophosphamide (N; %) 2 11.1 2 5.9
Mycophenolate (N; %) 3 16.7 3 8.8
Azathioprine (N; %) 6 33.3 10 29.4
Methotrexate (N; %) 3 16.7 5 14.7
Rituximab (N; %) 5 27.8 10 29.4
Belimumab (N; %) 3 16.7 5 14.7
Thrombotic risk factors
Arterial hypertension (N; %) 7 38.9 10 29.4
Hyperlipidemia (N; %) 2 11.1 5 14.7
Smoking habit (N; %) 3 16.7 5 14.7
Diabetes (N; %) 0 0.0 0 0.0
Hormone replacement therapy (N; %) 0 0.0 0 0.0
Inherited thrombophilia (N; %) 0 0.0 0 0.0
*Biopsy-proven.
**After aPS/PT testing.
*** For at least 80% of the observation time.
No statistical difference was observed between the two groups.
S.D., standard deviation; N., number; aPS/PT, anti-phosphatidylserine/prothrombin; Ig, immunoglobulins; SLE, Systemic Lupus Erythematosus.
(presence of any additional risk factor, to include smoking,
arterial hypertension, hyperlipidemia, diabetes, immobilization).
Although we observed a trend for aPS/PT in conferring
an increased risk for TEs (crude HR 12.9, 95% CI 0.7–236.7;
p = 0.08), the results failed to reach statistical significance.
When focusing on IgG aPS/PT, we found that patients who
tested positive were at a significantly higher risk for TEs
(crude HR 19.6, 95% CI 1.1–357.6; p = 0.04) compared to
aPS/PT negative patients. When taking the whole follow-up
period into account by log-rang analysis, patients with aPS/PT
presented with a shorter time free from events. Patients with
TEs had a higher GAPSS when compared to those without [6
± 2.6 vs. 2 ± 5.4; p = 0.09]; however, this failed to reach
statistical significance.
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TABLE 2 | Main clinical characteristics of the three patients who developed thromboembolic events.
Patient Previous clinical SLE
manifestation
TEs aPL profile Treatment at the
time of TE
SLEDAI-2K time of last
appointment before TE




occipital area at the level of
the left hippocampal gyrus




HCQ, PDN 5mg 0 (last appointment 2
months before)
#2, F, 36 yrs Oral aphthosis,
photosentivity, malar rash,
pleurlal-pericarditis, LN
(class IV+V), join, skin
Ischemic stroke (middle
cerebral artery territory)
LA, aPS/PT IgG, IgM HCQ, PDN 5mg 2 (low C3, last appointment
3 months before)
#3, F, 38 yrs Photosentivity, malar rash,
sub-acute skin rash,
pericarditis, joints
Renal TMA LA, aPS/PT IgG, IgM HCQ, PDN 5mg,
MTX




TMA, thrombotic microangiopathy; aPL, antiphospholipid antibodies; LA, lupus anti-coagulant; aPS/PT, anti-phosphatidylserine/prothrombin; SLE, systemic lupus erythematosus; TE,
thrombotic event; F, Female; SLEDAI, systemic lupus erythematosus disease index; Ig, immunoglobulins; HCQ, hydroxychloroquine; PDN, prednisone; MTX, Methotrexate; anti-dsDNA,
anti-double strand DNA.
DISCUSSION
In clinical practice, assessing thrombotic risk is challenging for
patients who tested negative for aβ2GPI-dependent aPL. The
clinical course in persons with high-risk aPL profiles (triple
positive patients) has been well-described (8); the role of extra-
criteria aPL, with or without concomitant positive LA, and their
clinical impact on positive subjects has been the subject of debate
over the last decades, with heterogeneous conclusions (2).
To address this issue, we prospectively evaluated a cohort of
SLE patients followed at our Center. They were homogeneous
in terms of strict inclusion criteria and negative for solid assay
criteria aPL (aCL and aβ2GPI antibodies), regardless of their
LA status. Besides, aPS/PT positivity tests were confirmed 12
weeks apart. Our results show a relevant incidence of TEs during
the follow-up period, with the incidence of TEs at 5.8% after 2
years. The annualized incidence of TEs in SLE patients negative
for aβ2GPI-dependent aPL testing was 1.3%. When focusing on
patients who tested positive for aPS/PT, the incidence of TEs rises
to 16%, with an annualized incidence of 2.8%, with aPS/PT IgG
isotype strongly associated with an increased thrombotic risk.
To our knowledge, this is the first prospective clinical study that
addresses the incidence of TEs in patients positive for aPS/PT and
negative for aβ2GPI-dependent aPL testing. Interestingly, in our
cohort, LA positivity did not seem to confer an additional risk
for TEs.
Additionally, in a prospective study (9), Ruffatti et al. reported
that arterial hypertension and LA positivity were independent
risk factors for thrombosis when investigating the risk factors for
a first thrombotic event in aPL antibody carriers, most of whom
had an associated autoimmune disease. While it is clear that LA
positivity is associated with TEs (10), managing patients with
isolated LA still requires some considerations (11). Investigating
the comprehensive aPL profile of patients/carriers should be
mandatory, as the isolated positivity for LA has not been
unanimously associated with thrombosis (12) or with clinical
manifestations of APS (13). Similar findings were observed in
the Leiden thrombophilia case-control study (14), which showed
that LA positivity in the absence of aβ2GPI or anti-prothrombin
antibodies was not associated with an increased risk for deep
vein thrombosis. The association of aPS/PT with thrombosis,
especially venous thrombosis, was stronger in the LA positive
patients than in LA negative subjects. We observed that aPS/PT
was independently associated with thrombosis and pregnancy
loss after multivariate analysis (15).
This study has some limitations, including the number
of observed events in the relatively short follow-up and
sample size (albeit in line with the low prevalence of APS,
especially when focusing on subgroups of patients with specific
aPL profiles). For instance, while no statistical significance
was found when looking at the higher levels of GAPSS
in patients with TEs, this probably was due to sample
size. Furthermore, patients included in the study had SLE
in association with APS, which could have influenced the
outcome. These observations require further validation in
cohorts of patients without concomitant SLE. Investigation of
any change in aPS/PT titres after the second confirmation
was outside the scope of this study. These aspects were,
however, counterbalanced by the use of strict inclusion criteria
(including aPS/PT positivity confirmation at least 12 weeks) and
the prospective nature of the study. Finally, since consecutive
patients with SLE who met the inclusion criteria were
prospectively enrolled in the study, some degree of variability in
follow-up length was present. Future studies with a larger sample
population, homogenous follow-up duration, and accordingly
designed statistical analysis plans are warranted to obtain
definite conclusions.
This study observed a rate of TEs of 1.3% each year only in
aPS/PT positive patients. This prospective data is validated by
previous retrospective studies (3, 4) and suggests that aPS/PT
might confer an increased risk for the development of TEs
in SLE patients. Future research should investigate whether
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SLE patients with aPS/PT could benefit from tailored primary
thrombo-prophylaxis strategies to include anti-platelet agents.
Large clinical trials are needed in the future to test this hypothesis.
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